The Irrational Hatred of GLP-1 Drugs

ChatGPT says: Much of the backlash comes from emotion and identity, not data. GLP-1 drugs threaten a lot of narratives people hold about discipline, morality, and control.

They undermine the idea that weight and appetite are purely matters of willpower. For many, that’s unsettling because it means biology plays a far bigger role than effort or virtue. If a weekly injection can do what years of dieting couldn’t, that challenges an entire moral framework built around “earning” health.

There’s also envy and status anxiety in the mix. People who struggled for decades see others getting results fast and feel cheated. Cultural resentment then gets dressed up as “concern” about side effects or dependency.

When you strip away the moral and social baggage, GLP-1 drugs are just another tool—an effective one, backed by strong data on weight loss and metabolic health. The hate says more about our culture’s discomfort with biological solutions than about the drugs themselves.

The cultural backlash is mostly about identity, not evidence. GLP-1–based meds reduce appetite and improve metabolic risk in ways diet alone rarely matches. That undercuts willpower-centric narratives. People feel judged or leap to moral claims to defend their worldview. The clinical record doesn’t support the hate.

What the strongest trials actually show

1. Large, durable weight loss vs placebo. In the STEP-1 RCT, weekly semaglutide 2.4 mg produced a mean −14.9% weight loss at 68 weeks, far more than placebo, with expected GI side effects NEJM 2021 (PubMed).
2. Even larger losses with tirzepatide. SURMOUNT-1 reported mean losses up to ~20% at 72 weeks with tirzepatide, again with GI events the main tradeoff NEJM 2022 (PubMed).
3. Hard outcomes, not just pounds. The SELECT outcomes trial in 17,604 adults with overweight or obesity and established CVD but without diabetes found semaglutide 2.4 mg cut major adverse cardiovascular events by 20% over ~40 months NEJM 2023 (PubMed). This is why Wegovy now carries a cardiovascular risk-reduction indication.

Common criticisms and the evidence

“It’s a shortcut. People just regain.”

• Obesity is chronic. When medication stops, biology pushes weight up. In the STEP-1 extension, those who stopped semaglutide regained about two-thirds of lost weight over a year, but still netted a loss vs baseline and lost most of the cardiometabolic gains they’d earned STEP-1 extension 2022 (full text).
• That’s not a “gotcha.” It is how chronic diseases behave. Blood pressure rises when you stop antihypertensives. The rational frame is long-term management, not magical cures.

“The side effects are too scary.”

• GI effects are the main issue in trials and practice. Nausea, vomiting, diarrhea, constipation, early satiety. They are dose-related and often transient. Discontinuation rates remained single digits in major RCTs NEJM 2022.
• Gallbladder disease risk is increased at higher doses and longer use, especially in weight-loss settings. This shows up across randomized trials and pharmacovigilance meta-analysis 2022 (Frontiers FAERS 2025).
• Pancreatitis signals exist, but absolute risk is low and data are mixed. Most reviews conclude careful monitoring rather than alarmism, especially in patients with prior pancreatitis or heavy alcohol use Cleveland Clinic J Med 2025 (review 2025).
• Retinopathy concerns stem from SUSTAIN-6 in diabetics with rapid A1c drops; risk appears tied to speed of glycemic improvement, not a direct toxic effect. Titrate and coordinate with eye care in high-risk diabetes SUSTAIN-6 analysis (2025 review slides).
• Bone and lean mass. Weight loss of any kind reduces bone density and lean mass. With GLP-1s, fat loss dominates, but some lean loss occurs. Exercise, protein, and resistance training mitigate this. A randomized trial found liraglutide alone reduced hip BMD vs exercise, while combining exercise with liraglutide protected bone better than drug alone JAMA Netw Open 2024. Reviews recommend standard countermeasures during pharmacologic weight loss Tinsley 2025 review.

“Real change should come from lifestyle.”

• Every pivotal trial included structured lifestyle intervention on both arms. Drugs were additive, not a substitute NEJM 2021.
• Obesity biology is powerful. Pharmacology that lowers defended body weight can make lifestyle changes stick. Calling that “cheating” confuses moral preference with outcomes.

“The results won’t last.”

• Continuation matters. Multi-year data support maintenance with ongoing therapy and plateauing rather than rebound while on drug. Tirzepatide extension data show sustained losses approaching 3 years in many participants NEJM 2022 and follow-ups reported publicly; see summary of 3-year maintenance presented at EASO report.

Why the backlash feels so loud

1. Status and fairness. People who white-knuckled diets feel undercut. Envy dresses up as “concern.”
2. Control narratives. If appetite and weight are heavily biological, old moral hierarchies collapse. That’s unsettling.
3. Healthcare mistrust. Pharma profiteering is real. That does not negate trial results. It argues for price reform, not medical nihilism.

Rational takeaways

1. These drugs work and improve hard outcomes, not just the bathroom scale SELECT.
2. They have class-typical risks. Most are manageable with slow titration, surveillance for gallbladder issues, and basic countermeasures for bone and lean mass.
3. Stopping usually means partial regain. Plan for long-term management, exactly how we treat hypertension or dyslipidemia.
4. Pair the med with resistance training, adequate protein, fiber, and sleep. You keep more lean mass, bones do better, and the habit stack endures exercise + drug trial, review.

Where the debate should move

• Access and cost. Align coverage with outcomes proven in RCTs, especially for cardiometabolic risk reduction.
• Integrated care. Standardize strength training and nutrition support in every GLP-1 prescription.
• Better patient selection. Prior gallstone disease, pancreatitis history, severe reflux, pregnancy intent, and active diabetic retinopathy need careful handling or avoidance. That’s medicine, not morality.

Bottom line

If someone hates GLP-1s, it’s usually about worldview, not data. The evidence base is strong, the risks are real but navigable, and the benefits extend to cardiovascular events in high-risk patients. Treat the disease, protect lean mass and bone, and stop moralizing what is fundamentally biology.